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Perspective
Why Burden of Disease Studies?
The goal of any health system is to 
improve the level and distribution of 
health of its eligible population. This 
goal implies an ability to measure 
population health (including differences 
between subgroups and trends over 
time) and to assess the contribution 
of different diseases, injuries, and risk 
factors to health outcomes.
But to carry out such a needs 
assessment, diverse health outcomes 
have to be expressed in a common unit. 
While various “currencies” have been 
proposed, only time-based measures of 
health have literally withstood the test 
of time. Such measures may indicate 
time spent in different health states 
(health expectancy measures) or reflect 
“functional” time lost as a result of 
premature mortality and morbidity 
(health gap measures such as the 
disability-adjusted life year or DALY—
see Box 1).
Burden of disease studies invariably 
employ DALYs (or HALYs—health-
adjusted life years—as they are known 
in Canada), given their focus on 
quantifying the relative contribution 
of different causes to health loss. Such 
studies were first commissioned by 
the World Bank [1] and thereafter 
championed by the World Health 
Organization [2]. National burden 
of disease studies have now been 
completed by many high- and middle-
income countries, including the United 
States, Canada (in progress), Mexico, 
France, The Netherlands, Mauritius, 
Australia, and New Zealand [3–8]. 
The Burden of Disease in Mexico
A study by Gretchen Stevens and 
colleagues in this month’s PLoS 
Medicine reports on the burden of 
disease in Mexico [9]. Estimates of 
burden are reported for Mexico as a 
whole and for each of the country’s 
32 states (although for presentation 
in PLoS Medicine the results have 
largely been aggregated into six 
regions). Only Australia has previously 
reported subnational burden of disease 
estimates [4]. The “value added” by 
such studies reflects the reality that 
in many countries, state or provincial 
rather than national governments hold 
jurisdiction over health. 
Stevens and colleagues show 
substantial heterogeneity in health, and 
the relative contributions of different 
causes to health, across Mexico. These 
authors interpret their results in terms 
of epidemiological transition theory, 
with different regions being at different 
stages of the transition.  The transition 
is from a high mortality–high fertility 
demography dominated by childhood 
infectious diseases and nutritional 
deficiency disorders to a low mortality–
low fertility demography dominated 
by chronic diseases affecting older 
adults in particular. They show that 
the Southern region (and in particular 
the state of Chiapas), with the least 
developed economy and the highest 
proportion of indigenous inhabitants, 
is at an earlier stage of epidemiological 
transition than other regions. Tellingly, 
the Southern region not only has 
the highest rates of pre-transitional 
conditions (such as infectious diseases 
and nutritional deficiency disorders), 
but also has the highest rates of injury 
and chronic diseases—although the 
relative proportion of health loss 
attributable to these latter cause groups 
is lower than in other regions.
The Southern region also shows 
markedly high health losses from 
alcohol use, mediated in particular 
through cirrhosis. Indeed, the burden 
from alcoholic cirrhosis is unusually 
high throughout Mexico. Neither 
volume of alcohol consumed nor 
drinking pattern seems to explain this 
unusually high burden. Instead, the 
authors speculate, the high burden 
may be related to pulque, a traditional 
fermented alcoholic beverage. The 
authors also find an unusually high 
burden from obesity and type 2 
diabetes in Mexico as a whole, again 
highest in the Southern region. 
Unfortunately, detailed data on diet 
and physical activity levels are not 
available to explore this further.
Why Was Mexico Able to 
Undertake a Subnational Burden 
of Disease Study?
Mexico is fortunate in having invested 
for many years in high-quality health 
statistical systems. Most impressive is 
the National Health and Nutrition 
Survey, which collected subnationally 
representative measured data from 
some 95,000 participants in 2006. Even 
so, chronic disease incidence and 
survival data (needed to calculate the 
morbidity component of the DALY) are 
largely lacking—as in most countries, 
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Linked Research Article
This Perspective discusses the 
following new study published in 
PLoS Medicine:
Stevens G, Dias RH, Thomas KJA, 
Rivera JA, Carvalho N, et al. (2008) 
Characterizing the epidemiological 
transition in Mexico: National and 
subnational burden of diseases, 
injuries, and risk factors. PLoS Med 
5(6): e125. doi:10.1371/journal.
pmed.0050125
Gretchen Stevens and colleagues 
estimate deaths and loss of healthy 
life years (measured in disability-
adjusted life years, DALYs) for Mexico 
as a whole and its 32 states.
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few chronic disease registries exist 
other than for cancer. 
The authors have made good use 
of modelling to close such data gaps, 
including extrapolating from data 
obtained in other comparable countries, 
but better empirical data are sorely 
needed in all countries. Mexico also 
lacks local health state valuation studies 
(to construct DALYs, health states must 
not only be described, but also valued). 
For health state valuation, however, 
it may be adequate to use data from 
other countries—there is little cultural 
variation in the relative value people 
assign to different health states [10]. 
In fact, burden of disease technology 
has matured remarkably over the past 
decade. Better disease models are now 
available; adjustment for comorbidity 
can now be made; and structured 
workbooks have been developed to ease 
the data management task [11,12].
Why Should Other Countries 
Follow Suit?
From a health policy perspective, 
burden of disease studies are clearly 
not the whole story. Nevertheless, 
as every clinician knows, diagnosis 
must come before treatment. To 
give one example from Stevens and 
colleagues’ study: the unacceptable 
burden of childhood malnutrition and 
infection (diarrhoea and pneumonia 
in particular) in Chiapas state calls 
for urgent and sustained action to 
improve water supplies, sanitation, 
housing, and access to high-quality 
primary health care—especially for 
disadvantaged, largely indigenous, and 
rural communities within that state.
Other countries can also use burden 
of disease studies to reveal previously 
hidden or neglected health problems 
within their own borders. Repeating 
the study at regular (five to ten-year) 
intervals can determine whether 
policies intended to improve levels of 
health and close gaps between regions 
and ethnic groups are in fact working. 
Most importantly, both the Mexican 
and Australian burden of disease 
studies show that such analyses do 
not have to be restricted to the 
national level. Instead, studies should 
align with the level of jurisdiction at 
which important resource allocation 
decisions are made and priorities are 
set. Given this alignment, burden of 
disease studies will provide a policy-
relevant, internally consistent set of 
epidemiological estimates (and, ideally, 
projections) as well as a standard 
metric with which the full range of 
health outcomes and risks can be 
described and valued. Mexico has 
taken the lead in demonstrating how 
subnational burden of disease studies 
can be done and how their output 
can be used to inform policy. Other 
countries would benefit from adopting 
a similar approach.  
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Box 1. The DALY
The DALY is a summary measure of population health that integrates health losses resulting from premature mortality with those 
resulting from functional limitation (disability). It is, in essence, a measure of unmet need.
The DALYs lost (by a specified population in a specified period) from each disease, injury, or risk factor are calculated as the sum of 
the years of life lost to premature mortality (YLL) and the equivalent number of “healthy” years lost to functional limitation (YLD) for 
incident cases of the condition, using the equation: 
DALY  =  YLL  +  YLD 
where YLL = number of deaths × standard life expectancy at age of death, 
and YLD = incidence × duration × severity weight.
Thus one DALY represents the loss of one year of healthy life. 
Estimating DALYs requires extensive—and internally consistent—epidemiological data. As well as estimates of incidence and 
mortality, data are needed on the severity distribution of the functional limitation associated with each condition, taking into account 
both stage of disease (or the presence of complications) and access to and effectiveness of current health care and disability support 
services. 
Finally, disability (severity) weights must be assigned to each category of functional limitation, based on social preferences for time 
spent with such limitation relative to full health on the one hand and death on the other. 
A number of value choices need to be made when estimating DALYs. These include whether to use the same “ideal” life expectancy 
standard for all populations; whether to use the same disability weight for everyone living a year in a specified health state (or to 
weight differently depending, for example, on the age at which the year is lived); and whether to discount the stream of future health 
losses to net present value (and, if so, what discount rate to use).  